+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07665450

Phase 3 Study Comparing Ramantamig Plus Daratumumab Versus Standard Daratumumab-Based Treatments in Newly Diagnosed Multiple Myeloma Without Planned Stem Cell Transplant

Led by Janssen Research & Development, LLC · Updated on 2026-11-03

1000

Participants Needed

103

Research Sites

230 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new treatment called ramantamig-D for people newly diagnosed with multiple myeloma, a type of blood cancer affecting plasma cells. This study compares ramantamig-D with standard treatments that include combinations of daratumumab, bortezomib, lenalidomide, and dexamethasone in participants who are not planned to undergo stem cell transplant as their first therapy. Participants will be randomly assigned to receive either ramantamig-D by subcutaneous injection or one of two standard treatment regimens chosen by their doctor DVRd daratumumab, bortezomib, lenalidomide, and dexamethasone or DRd daratumumab, lenalidomide, and dexamethasone. The study will measure how long participants live without their disease worsening and the percentage achieving a complete response with no detectable cancer cells up to 12 months. During the trial, participants will be monitored for progression-free survival for about 62 months and other outcomes like overall survival and quality of life for up to 100 months. Assessments will include disease response rates, adverse events, and patient-reported outcomes. Participants will have scheduled visits and evaluations to carefully track treatment effects and safety throughout the study.

CONDITIONS

Brief Title

A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here